Cargando...

Immune Checkpoint Inhibitors in Non‐Small Cell Lung Cancer

Historically, lung cancer was long considered a poorly immunogenic malignancy. In recent years, however, immune checkpoint inhibitors have emerged as promising therapeutic agents in non‐small cell lung cancer (NSCLC). To date, the best characterized and most therapeutically relevant immune checkpoin...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Herzberg, Benjamin, Campo, Meghan J., Gainor, Justin F.
Formato: Artigo
Idioma:Inglês
Publicado: Wiley-Blackwell 2016
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5313266/
https://ncbi.nlm.nih.gov/pubmed/27534574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0189
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!